Anti-PTGFRN antibody

Anti-PTGFRN antibody

• DataSheet
• Material Safety Data Sheets (MSDS)

Rabbit Polyclonal to Human PTGFRN

WB

Human EWI-F / PTGFRN

prostaglandin F2 receptor inhibitor antibody; PTGFRN antibody; CD315 antibody; CD9P-1 antibody; EWI-F antibody; FPRP antibody; SMAP-6 antibody; CD9 partner 1 antibody; glu-Trp-Ile EWI motif-containing protein F antibody; prostaglandin F2 receptor negative regulator antibody; prostaglandin F2-alpha receptor regulatory protein antibody; prostaglandin F2-alpha receptor-associated protein antibody; prostaglandin F2 receptor negative regulator antibody; Ptgfrn antibody; DN-358O3.4 antibody; 4833445A08Rik antibody; AU042434 antibody; CD9P-1 antibody; FPRP antibody; Trim45 antibody; prostaglandin F2-alpha receptor regulatory protein antibody; prostaglandin F2-alpha receptor-associated protein antibody; FPRP antibody; CD315 antibody; EWI-F antibody; CD9P-1 antibody; SMAP-6 antibody; FPRP antibody; CD9P-1 antibody; Trim45 antibody; AU042434 antibody; 4833445A08Rik antibody

Rabbit IgG

Produced in rabbits immunized with a synthetic peptide corresponding to the center region of the Human EWI-F / PTGFRN. The IgG fraction of the cell culture supernatant was purified by Protein A affinity chromatography.

Polyclonal

0.2 μm filtered solution in PBS

This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free.
Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.

EWI-F, also known as PTGFRN, is inversely related to the loss of CD9. Its expression correlates with the metastatic status of hLT (n=55). EWI-F inhibits the binding of prostaglandin F2-alpha (PGF2-alpha) to its specific FP receptor, by decreasing the receptor number rather than the affinity constant. EWI-F expression positively correlates with the metastatic status of hLT, and that the upregulation of EWI-F expression could be one of the mechanisms underlying the loss of CD9 in solid tumours.